Norditropin Nordiflex (Somatropin)

Somatropin, the active ingredient in Norditropin Nordiflex, is a growth hormone presented as a liquid formulation for subcutaneous use. It is used to treat growth hormone deficiency and related growth disorders in children and adolescents. GNH USA supplies Norditropin Nordiflex as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Norditropin Nordiflex is a recombinant human growth hormone used in conditions affecting growth and development. - Growth hormone deficiency: promotes linear growth and improves body composition in children with insufficient endogenous GH. - Turner syndrome: helps increase height and improve growth velocity in affected females. - Chronic renal insufficiency: supports growth in pediatric patients with renal disease. - Prader‑Willi syndrome: aids in achieving better growth outcomes and body composition. - Short stature of idiopathic origin: stimulates growth when the cause of short stature is unknown.

Somatropin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the injection site. - Headache: occasional mild to moderate headache. - Edema: transient swelling of hands, feet, or ankles. - Joint stiffness: temporary stiffness, especially in larger joints.

Serious or Rare Side Effects: - Intracranial hypertension: symptoms include headache, visual disturbances, nausea. - Slipped epiphysis (epiphyseal plate closure): may cause bone pain and growth arrest. - Glucose intolerance or diabetes mellitus: altered glucose metabolism requiring monitoring.

Before initiating therapy, clinicians should assess patient suitability and monitor response. - Monitor IGF‑1 levels: adjust dose based on serial measurements to avoid excess exposure. - Screen for malignancy: avoid use in patients with active cancer due to potential proliferative effects. - Assess for intracranial hypertension: discontinue if signs of increased intracranial pressure appear. - Evaluate glucose metabolism: monitor fasting glucose and HbA1c in at‑risk individuals. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Somatropin may interact with several agents, altering efficacy or safety.

Major Interactions (Avoid): - Glucocorticoids: may blunt the growth‑promoting effect of somatropin. - Insulin or oral hypoglycemics: GH can antagonize insulin action, requiring dose adjustments.

Moderate Interactions (Monitor Closely): - Estrogen therapy: can increase IGF‑1 levels, potentially enhancing GH effects. - Thyroid hormone replacement: GH therapy may increase the requirement for levothyroxine.